登录 | 注册    关注公众号  
微信公众号
搜索
 > 【EGFRvIII】

EGFRvIII信息

英文名称:Epidermal growth factor receptor variant III
中文名称:表皮生长因子受体变体III
靶点别称
上市药物数量:0
临床药物数量:13
最高研发阶段:临床二期

EGFRvIII分子别名

EGFRvIII

EGFRvIII分子背景

The epidermal growth factor receptor (EGFR; ErbB-1; HER1 in humans) is the cell-surface receptor for members of the epidermal growth factor family (EGF-family) of extracellular protein ligands. The epidermal growth factor receptor is a member of the ErbB family of receptors, a subfamily of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). Mutations affecting EGFR expression or activity could result in cancer.
The type III EGF deletion mutant receptor (EGFRvIII) is the most common mutation and was first identified in primary human glioblastoma tumors. This tumor-specific antigen is ligand-independent, contains a constitutively active tyrosine kinase domain, and has been shown to be present in a number of human malignancies. EGFRvIII has been selected as a target for CAR-modified T-cell studies in recent years.

EGFRvIII临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定